NEW YORK, Feb. 12, 2025 /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public.

So What: If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

ANDOVER, Mass., Feb. 3, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on January 28, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 34,884 shares of its common stock and an aggregate of 23,192 restricted stock units to 3 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.

NEW YORK, Jan. 31, 2025 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public.

So What: If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether TransMedics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

LOS ANGELES, Jan. 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ: TMDX) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. TransMedics is the subject of a report issued by Scorpion Capital on January 10, 2025. The report claims that in "20 years of shorting, TransMedics is the most extreme and grotesque healthcare fraud we have encountered, not only for its scale, but because it is predicated on the exploitation of the most vulnerable patients – the terminally ill, desperate for an organ. The 'lucky' patients who receive a diseased, damaged organ rejected by reputable surgeons and centers … are oblivious to the cesspool of perverse, secret incentives that steered the organ their way."

NEW YORK, Jan. 27, 2025 /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public.

So What: If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether TransMedics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, Jan. 19, 2025 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public.

So What: If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

RADNOR, Pa., Jan. 17, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of TransMedics Group, Inc. (NASDAQ: TMDX) ("TransMedics").

On January 10, 2025, Scorpion Capital issued a short seller report on TransMedics. Specifically, the report alleged wrongdoing with respect to TransMedics' business practices, including fraudulent billing schemes, off-label misuse of its devices, and reliance on kickbacks to drive sales. The report also highlighted ongoing regulatory scrutiny, with reports of investigations by the DOJ, IRS, and state attorney generals into Medicare fraud linked to organ acquisition costs. Additionally, the report makes claims regarding customer dissatisfaction, including prominent transplant centers discontinuing their use of TransMedics' devices citing concerns over their clinical value.

NEW YORK, Jan. 14, 2025 /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public.

So What: If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

SAN FRANCISCO, Jan. 14, 2025 /PRNewswire/ -- Shares of TransMedics, Group Inc. (NASDAQ: TMDX) suffered a sharp decline over the past two trading days following the release of a damaging report by activist short-seller Scorpion Capital. TransMedics' stock price has dropped $9.84, or 13%, since Scorpion released a report, titled "Walk Like An Egyptian," leveling serious allegations against the company, including fraud, organ trafficking, and off-label device misuse.

ANDOVER, Mass., Jan. 13, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion Capital on January 10, 2025.

ANDOVER, Mass.  , Dec. 23, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 13, 2025, at 2:15 p.m. Pacific Standard Time / 5:15 p.m. Eastern Standard Time.

ANDOVER, Mass., Dec. 12, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 9, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 20,612 shares of its common stock and an aggregate of 13,576 restricted stock units to 3 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants included stock options to purchase 18,922 shares of TransMedics' common stock and 12,463 restricted stock units granted to Gerardo Hernandez, the Company's Chief Financial Officer. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.

SAN DIEGO, Dec. 3, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving TransMedics Group, Inc. (NASDAQ: TMDX) focused on whether the company as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.

If you have information that could assist in the TransMedics investigation or if you are a TransMedics investor who suffered a loss and would like to learn more, you can provide your information here:

ANDOVER, Mass., Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024. In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon. To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025, before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagement until March 31, 2026. TransMedics also updated its 2024 financial outlook.

ANDOVER, Mass., Nov. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it will host an Investor & Analyst Day in New York City on Tuesday, December 10, 2024, at 10:00 AM ET.

Waleed Hassanein, MD., President and Chief Executive Officer, and members of the leadership team will present an overview of TransMedics' growth strategy, clinical pipeline, and operations.  

ANDOVER, Mass., Nov. 19, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024, at 4:00 p.m. Eastern Time.

SAN DIEGO, Nov. 1, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving TransMedics Group, Inc. (NASDAQ: TMDX) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.

If you have information that could assist in the TransMedics investigation or if you are a TransMedics investor who suffered a loss and would like to learn more, you can provide your information here:

ANDOVER, Mass., Oct. 29, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 23, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 2,969 shares of its common stock and an aggregate of 1,937 restricted stock units to 6 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.